Senseonics (NYSE:SENS) this week announced that it partnered with Geo-Med to provide access to the Eversense continuous glucose monitor to more than 9 million veterans and U.S. government staff.
The company’s Eversense device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days.
Get the full story at our sister site, Drug Delivery Business News.
The post Senseonics partners to provide veterans with Eversense CGM appeared first on MassDevice.